We are live on
!
Find out more
SCM
Soleus Capital Management Portfolio holdings
AUM
$2.9B
1-Year Est. Return
169.69%
This Fund
S&P 500
This Quarter
Est. Return
+14.25%
1 Year Est. Return
+169.69%
3 Year Est. Return
+507.65%
5 Year Est. Return
+746.04%
10 Year Est. Return
–
AUM
$966M
AUM Growth
+$269M
(+39%)
Cap. Flow
+$147M
Cap. Flow
% of AUM
15.21%
Top 10 Holdings %
Top 10 Hldgs %
49.6%
Holding
104
New
32
Increased
25
Reduced
14
Closed
27
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Smith & Nephew
SNN
|
+$27.6M |
| 2 |
Rigel Pharmaceuticals
RIGL
|
+$20.3M |
| 3 |
SI-BONE Inc
SIBN
|
+$18.8M |
| 4 |
Natera
NTRA
|
+$14.1M |
| 5 |
Jasper Therapeutics
JSPR
|
+$13.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVRx
CVRX
|
+$18.6M |
| 2 |
Vericel Corp
VCEL
|
+$16.9M |
| 3 |
Eli Lilly
LLY
|
+$14.3M |
| 4 |
HCA Healthcare
HCA
|
+$8.29M |
| 5 |
Krystal Biotech
KRYS
|
+$8.09M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.4% |
| 2 | Miscellaneous | 17.18% |
| 3 | Consumer Staples | 1.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $159M | 16.42% |
+2,080,000
| New | +$173M |
|
|
FOCL
2
EDAP TMS S.A.
FOCL
$187M
| $58.8M | 6.09% |
5,312,222
+177,792
| +3% | +$2.01M |
|
|
ISEE
3
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $51.8M | 5.36% |
2,127,043
+12,315
| +0.6% | +$270K |
|
|
ACLX
4
DELISTED
Arcellx
ACLX
| $38.5M | 3.98% |
1,248,147
+145,700
| +13% | +$4.42M |
|
5
Charles River Laboratories
CRL
$13B
| $31.5M | 3.26% |
156,096
+54,246
| +53% | +$12.3M |
|
|
EXAS
6
DELISTED
Exact Sciences
EXAS
| $31M | 3.21% |
456,500
+169,200
| +59% | +$10.9M |
|
7
United Therapeutics
UTHR
$21.5B
| $30.5M | 3.16% |
136,235
+7,967
| +6% | +$1.96M |
|
8
iRadimed
IRMD
$1.05B
| $30.4M | 3.15% |
773,694
+28,690
| +4% | +$1.04M |
|
|
9
Smith & Nephew
SNN
$11.7B
| $27.1M | 2.8% |
+970,200
| New | +$27.6M |
|
10
Organogenesis Holdings
ORGO
$188M
| $21M | 2.17% |
9,853,063
+2,490,000
| +34% | +$6.15M |
|
|
11
SI-BONE Inc
SIBN
$831M
| $20.9M | 2.16% |
+1,060,983
| New | +$18.8M |
|
|
SRDX
12
DELISTED
Surmodics
SRDX
| $20.3M | 2.11% |
892,678
+117,367
| +15% | +$3.02M |
|
13
CVS Health
CVS
$121B
| $18.1M | 1.87% |
243,554
+148,800
| +157% | +$12.5M |
|
14
Celcuity
CELC
$4.05B
| $17.3M | 1.79% |
1,687,933
+477,705
| +39% | +$5.24M |
|
|
15
Rigel Pharmaceuticals
RIGL
$829M
| $16.9M | 1.75% |
+1,280,302
| New | +$20.3M |
|
16
Axogen
AXGN
$2.42B
| $16.8M | 1.74% |
1,779,998
+1,024,000
| +135% | +$9.37M |
|
|
17
Natera
NTRA
$50.6B
| $16.3M | 1.69% |
+294,200
| New | +$14.1M |
|
|
RETA
18
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $15.9M | 1.64% |
+174,592
| New | +$10.2M |
|
|
SGEN
19
DELISTED
Seagen Inc. Common Stock
SGEN
| $14.4M | 1.49% |
+71,000
| New | +$11.4M |
|
20
Vaxcyte
PCVX
$8.81B
| $14.3M | 1.48% |
380,250
-7,700
| -2% | -$327K |
|
21
SkinHealth Systems
SKIN
$87.8M
| $13.8M | 1.43% |
1,089,952
-286,416
| -21% | -$3.31M |
|
|
22
Jasper Therapeutics
JSPR
$19M
| $13.5M | 1.4% |
+745,498
| New | +$13.8M |
|
|
EPIX
23
DELISTED
ESSA Pharma
EPIX
| $12.3M | 1.27% |
4,145,117
+275,725
| +7% | +$810K |
|
|
BCAB
24
DELISTED
BIOATLA INC
BCAB
| $11.6M | 1.2% |
86,424
+2,016
| +2% | +$363K |
|
25
Humana
HUM
$47.6B
| $11.5M | 1.19% |
23,750
-3,000
| -11% | -$1.48M |
|
Similar funds
GA
LSA
7WCP
ACM
HWA
JC
WPW
BWL
Soleus Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Soleus Capital Management held 104 positions worth $966M, up 39% from $697M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Soleus Capital Management deployed $147M of net new capital in Q1 2023, opening 32 new positions and adding to 25 existing holdings. Its largest new stake was Smith & Nephew: 970,200 shares worth $27.1M.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 97% a quarter earlier, followed by Miscellaneous and Consumer Staples.
On the sell side, the largest reduction was Vericel Corp, an estimated $16.9M trimmed.
- Soleus Capital Management's largest Q1 2023 buy was Smith & Nephew: 970,200 shares worth $27.1M.
- Soleus Capital Management added most to CVS Health in Q1 2023, an estimated $12.5M increase.
- Soleus Capital Management's biggest Q1 2023 reduction was Vericel Corp, cutting an estimated $16.9M.
- Soleus Capital Management fully exited CVRx in Q1 2023, selling an estimated $18.6M.
- Soleus Capital Management's ten largest holdings make up 50% of its $966M portfolio in Q1 2023.
- Soleus Capital Management opened 32 new positions and closed 27 in Q1 2023.
- Soleus Capital Management's portfolio value rose 39% quarter-over-quarter to $966M.
Based on Soleus Capital Management's 13F filing for Q1 2023, filed 15 May 2023.